Table 1 Comparisons of clinical information between UC and CD patients

Response, n (%)

88(62.41%)

41(59.42%)

47(65.28%)

0.492

Age (years)

38.00(23.00–51.00)

48.00(33.50–55.50)

26.00(21.00–39.75)

 < 0.001

Male, n (%)

85(60.28%)

38(55.07%)

47(65.28%)

0.233

BMI (kg/m²)

19.52 ± 3.46

20.54 ± 3.22

18.54 ± 3.43

0.001

Temperature > 37.8 °C, n (%)

45(31.91%)

19(27.54%)

26(36.11%)

0.285

ESR (mm/h)

50.23 ± 30.63

49.72 ± 30.80

50.71 ± 30.68

0.849

CRP (mg/L)

44.40(15.00–77.21)

55.10(14.99–85.78)

39.89(15.16–69.58)

0.338

Hb (g/L)

106.20 ± 25.79

107.93 ± 25.55

104.54 ± 26.08

0.438

Alb (g/L)

33.71 ± 6.92

33.37 ± 6.55

34.04 ± 7.29

0.566

CMV seropositivity, n (%)

10(7.09%)

10(14.49%)

0(0.00%)

0.001

Disease duration (months)

12.00(6.00–48.00)

12.00(4.00–57.00)

12.00(6.00–45.00)

0.831

Stool frequency (n/day)

6(4–10)

8(6–12)

5(2–8)

 < 0.001

Bloody stools, n (%)

97(68.79%)

69(100.00%)

28(38.89%)

 < 0.001

Parenteral manifestations, n (%)

42(29.79%)

12(17.39%)

30(41.67%)

0.002

Colonic dilatation, n (%)

15(10.64%)

11(15.94%)

4(5.56%)

0.057

SATI (cm²/m²)

24.36(12.44–39.87)

29.02(21.84–44.18)

19.84(9.18–33.94)

 < 0.001

VATI (cm²/m²)

16.94(9.18–25.41)

18.66(12.27–31.60)

14.60(8.49–21.82)

0.027

PSAI (cm²/m²)

0.96(0.71–1.35)

1.19(0.96–1.57)

0.81(0.57–0.96)

 < 0.001

MATI (cm²/m²)

4.33 ± 2.13

4.87 ± 2.08

3.81 ± 2.06

0.003

MFI (cm²/m²)

0.71(0.54–1.00)

0.68(0.56–0.81)

0.75(0.51–1.13)

0.090